var title_f8_21_8528="Transducer position apical 4 ch";
var content_f8_21_8528=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F65589&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F65589&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transducer positon for apical four-chamber view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 356px; height: 364px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transducer position and beam plane used to image the heart in the apical four-chamber view is shown. The transducer is on the apex impulse location and is directed toward the right shoulder.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_21_8528=[""].join("\n");
var outline_f8_21_8528=null;
var title_f8_21_8529="Scrotal incision during vasectomy";
var content_f8_21_8529=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F55770&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F55770&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Scrotal incision during vasectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 339px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Local anesthesia is instilled and a small incision is made overlying the vas.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Clenney, TL, Higgins, JC. Vasectomy Techniques. American Family Physician 1999; 60:137. Copyright &copy;1999 Timothy Clenney, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_21_8529=[""].join("\n");
var outline_f8_21_8529=null;
var title_f8_21_8530="Sodium lactate: Drug information";
var content_f8_21_8530=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sodium lactate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?4/4/4163?source=see_link\">",
"    see \"Sodium lactate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F221843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Alkalinizing Agent, Parenteral",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F221836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Bicarbonate precursor:",
"     </b>",
"     I.V.: Dosage depends on degree of acidosis",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F221837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F221830\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion: 18.7 g (1000 mL [DSC]) [contains sodium 167 mEq and lactate 167 mEq per 1000 mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [concentrate, preservative free]: 560 mg/mL (10 mL) [contains sodium 5 mEq and lactate 5 mEq per 1 mL]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F221822\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F221832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The rate of I.V. infusion should not exceed 300 mL/hour of the",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      6",
"     </sub>",
"     molar injection",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F221846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Cimetidine.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F221831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Source of bicarbonate for prevention and treatment of mild-to-moderate metabolic acidosis",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300059\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6223004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Alkalinizing Agents may decrease the excretion of Amphetamines.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Flecainide: Sodium Lactate may increase the serum concentration of Flecainide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: Alkalinizing Agents may increase the serum concentration of QuiNINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F221826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13888278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F221840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use caution",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F9842508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products may contain sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Sodium Lactate)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60% (1 mL): $0.27",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Sodium Lactate Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mEq/mL (10 mL): $2.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     167 mEq/L (1000 mL): $5.96",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10267 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-C1CDB4E621-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_21_8530=[""].join("\n");
var outline_f8_21_8530=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221843\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221836\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221837\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221830\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221822\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221832\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221846\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221831\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300059\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6223004\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221826\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13888278\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221840\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9842508\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323870\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10267\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10267|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?4/4/4163?source=related_link\">",
"      Sodium lactate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_21_8531="SEER incidence of thyroid cancer by race and sex";
var content_f8_21_8531=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F58551&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F58551&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 699px\">",
"   <div class=\"ttl\">",
"    SEER observed incidence, SEER delay adjusted incidence and US death rates*, cancer of the thyroid, by race and sex",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 679px; height: 457px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Source: SEER 9 areas and US Mortality Files (National Center for Health Statistics, CDC).",
"     <br/>",
"     Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).",
"     <br/>",
"     Regression lines and APCs are calculated using the Joinpoint Regression Program Version 3.5, April 2011, National Cancer Institute.",
"     <br/>",
"     The APC is the Annual Percent Change for the regression line segments. The APC shown on the graph is for the most recent trend.",
"     <br/>",
"     &Delta; The APC is significantly different from zero (p&lt;0.05).",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Howlader N, Noone AM, Krapcho M, et al (Eds). SEER Cancer Statistics Review, 1975-2008, National Cancer Institute. Bethesda, MD. Full report available at:",
"     <a href=\"file://seer.cancer.gov/csr/1975_2008/\" style=\"FONT-STYLE: italic\" target=\"_blank\">",
"      file://seer.cancer.gov/csr/1975_2008/",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_21_8531=[""].join("\n");
var outline_f8_21_8531=null;
var title_f8_21_8532="M mode aorta hypertrophic CM";
var content_f8_21_8532=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F75078&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F75078&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    M-mode echocardiogram in hypertrophic cardiomyopathy with dynamic obstruction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 386px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In hypertrophic cardiomyopathy there is altered diastolic function, with slow left ventricle relaxation and left atrial (LA) emptying; the aortic (Ao) root diastolic motion is altered so that early rapid posterior motion is not seen until atrial contraction. This pattern is the counterpart of the a-wave dominant diastolic pattern seen by Doppler. The net forward motion of the Ao is adequate, but the timing and distribution have changed. The initial opening of the aortic valve (AV) is normal but shows a prominent midsystolic closure or notch, which coincides with the onset of subaortic obstruction induced by the systolic contact of the mitral valve with the septum; the AV often reopens for the second half of systole.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_21_8532=[""].join("\n");
var outline_f8_21_8532=null;
var title_f8_21_8533="Chlorthalidone: Patient drug information";
var content_f8_21_8533=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Chlorthalidone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/14/26854?source=see_link\">",
"     see \"Chlorthalidone: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/46/35557?source=see_link\">",
"     see \"Chlorthalidone: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F150695\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Thalitone&reg; [DSC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F150696\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Chlorthalidone&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10021787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10021789\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691367",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to get rid of extra fluid.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10021788\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701790",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to chlorthalidone or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfa (sulfonamide) allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703777",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10021793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697204",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor. This drug may raise blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Watch for gout attacks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10021794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698217",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low potassium levels like muscle pain or weakness, muscle cramps, or a heartbeat that does not feel normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10021796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699072",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low potassium.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10021791\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695872",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause you to pass urine more often. To keep from having sleep problems, try to take before 6 pm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10021792\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10021797\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10021798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11603 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-2.133.93.82-ACA0B7D5D4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_21_8533=[""].join("\n");
var outline_f8_21_8533=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150695\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150696\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021787\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021789\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021788\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021793\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021794\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021796\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021791\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021792\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021797\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021798\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/14/26854?source=related_link\">",
"      Chlorthalidone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/46/35557?source=related_link\">",
"      Chlorthalidone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_21_8534="Patient consent form - page 2";
var content_f8_21_8534=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F72823&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F72823&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 587px\">",
"   <div class=\"ttl\">",
"    Patient consent form - page 2",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 567px; height: 790px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_21_8534=[""].join("\n");
var outline_f8_21_8534=null;
var title_f8_21_8535="Haley-Haley histology";
var content_f8_21_8535=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F75555&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F75555&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Histopathologic findings in Hailey-Hailey disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Skin biopsy from the axilla of a 58-year-old woman who complained of a chronic erosive irritated intertriginous eruption for years. The histologic examination reveals suprabasilar clefting of the epidermis; full thickness acantholysis with some dyskeratosis near the granular layer; and sparse perivascular lymphocytic infiltrate in the papillary dermis with scattered eosinophils. These findings are typical of Hailey-Hailey disease. Direct immunoflourescence was negative.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Nathan Jones, MSIV, Dermatlas;",
"     <a href=\"file://www.dermatlas.org\" target=\"_blank\">",
"      file://www.dermatlas.org",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_21_8535=[""].join("\n");
var outline_f8_21_8535=null;
var title_f8_21_8536="Budesonide and formoterol: Drug information";
var content_f8_21_8536=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Budesonide and formoterol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?9/54/10086?source=see_link\">",
"    see \"Budesonide and formoterol: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/39/43638?source=see_link\">",
"    see \"Budesonide and formoterol: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F3071871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Symbicort&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F142769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Symbicort&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F142784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Beta;",
"      <sub>",
"       2",
"      </sub>",
"      Agonist",
"     </li>",
"     <li>",
"      Beta;",
"      <sub>",
"       2",
"      </sub>",
"      -Adrenergic Agonist, Long-Acting",
"     </li>",
"     <li>",
"      Corticosteroid, Inhalant (Oral)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F142772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Asthma:",
"     </b>",
"     Oral inhalation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      U.S. labeling:",
"     </b>",
"     Symbicort&reg; 80/4.5, Symbicort&reg; 160/4.5: Two inhalations twice daily (maximum: 4 inhalations/day). Recommended starting dose combination is determined according to asthma severity. In patients not adequately controlled on the lower combination dose following 1-2 weeks of therapy, consider the higher dose combination.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Canadian labeling:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Symbicort&reg; 100 Turbuhaler&reg; [CAN; not available in U.S.], Symbicort&reg; 200 Turbuhaler&reg; [CAN; not available in U.S.]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Initial: 1-2 inhalations twice daily until symptom control, then titrate to lowest effective dosage to maintain control",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Maintenance: 1-2 inhalations once or twice daily (maximum: 8 inhalations/day as temporary treatment in periods of worsening asthma)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Symbicort&reg; Maintenance and Reliever Therapy (Symbicort&reg; SMART):",
"     <b>",
"      Note:",
"     </b>",
"     Not approved in the U.S.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <i>",
"      Maintenance:",
"     </i>",
"     Symbicort&reg; 100 Turbuhaler&reg; [CAN]",
"     <b>",
"      or",
"     </b>",
"     Symbicort&reg; 200 Turbuhaler&reg; [CAN]: 1-2 inhalations twice daily",
"     <b>",
"      or",
"     </b>",
"     2 inhalations once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <i>",
"      Reliever therapy:",
"     </i>",
"     Symbicort&reg; 100 Turbuhaler [CAN]",
"     <b>",
"      or",
"     </b>",
"     Symbicort&reg; 200 Turbuhaler&reg; [CAN]: 1 additional inhalation as needed, may repeat if no relief for up to 6 inhalations total (maximum: 8 inhalations/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      COPD:",
"     </b>",
"     Oral inhalation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      U.S. labeling:",
"     </b>",
"     Symbicort&reg; 160/4.5: Two inhalations twice daily (maximum: 4 inhalations/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Canadian labeling:",
"     </b>",
"     Symbicort&reg; 200 Turbuhaler&reg; [CAN; not available in U.S.]: Two inhalations twice daily (maximum: 4 inhalations/day)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F142779\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/39/43638?source=see_link\">",
"      see \"Budesonide and formoterol: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Asthma:",
"     </b>",
"     Oral inhalation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children 5-11 years (NIH Guidelines): Symbicort&reg; 80/4.5: Two inhalations twice daily. Do not exceed 4 inhalations per day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3062966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15682318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F7310404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied). However, close monitoring of patients with hepatic disease may be warranted due to hepatic metabolism of both agents.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F142757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aerosol for oral inhalation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Symbicort&reg; 80/4.5: Budesonide 80 mcg and formoterol fumarate dihydrate 4.5 mcg per actuation (6.9 g) [60 metered inhalations]; budesonide 80 mcg and formoterol fumarate dihydrate 4.5 mcg per actuation (10.2 g) [120 metered inhalations]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Symbicort&reg; 160/4.5: Budesonide 160 mcg and formoterol fumarate dihydrate 4.5 mcg per actuation (6 g) [60 metered inhalations]; budesonide 160 mcg and formoterol fumarate dihydrate 4.5 mcg per actuation (10.2 g) [120 metered inhalations]",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F5950028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Powder for oral inhalation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Symbicort&reg; 100 Turbuhaler&reg;: Budesonide 100 mcg and formoterol dihydrate 6 mcg per inhalation (available in 60 or 120 metered doses) [delivers ~80 mcg budesonide and 4.5 mcg formoterol per inhalation; contains lactose]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Symbicort&reg; 200 Turbuhaler&reg;: Budesonide 200 mcg and formoterol dihydrate 6 mcg per inhalation (available in 60 or 120 metered doses) [delivers ~160 mcg budesonide and 4.5 mcg formoterol per inhalation; contains lactose]",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at file://www1.astrazeneca-us.com/pi/symbicort.pdf, must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F142759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Symbicort&reg; 80/4.5, Symbicort&reg; 160/4.5: Prior to first use, inhaler must be primed by releasing 2 test sprays into the air; shake well for 5 seconds before each spray. Inhaler must be reprimed if not used for &gt;7 days or if it has been dropped. Shake well for 5 seconds before each use. Discard inhaler after the labeled number of inhalations have been used or within 3 months after removal from foil pouch (do not use the &ldquo;float test&rdquo; to determine amount remaining in canister).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Symbicort&reg; Turbuhaler&reg; [CAN; not available in U.S.]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     To &ldquo;load&rdquo; inhaler: Turn grip on inhaler as far as it will move in one direction, then turn in opposite direction as far as it will go (inhaler is &ldquo;loaded&rdquo; with a dose, indicated by a &ldquo;click&rdquo;). Prior to first use, this procedure should be done twice, it does not need to be repeated with subsequent uses even when not used regularly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Delivery of dose: Instruct patient to place mouthpiece gently between teeth, closing lips around inhaler. Instruct patient to inhale deeply and hold breath held for 5-10 seconds. The amount of drug delivered is small, and the individual will not sense the medication as it is inhaled. Remove mouthpiece prior to exhalation. Patient should not breathe out through the mouthpiece. After use of the inhaler, patient should rinse mouth/oropharynx with water and spit out rinse solution.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F142758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of asthma in patients &ge;12 years of age where combination therapy is indicated; maintenance treatment of airflow obstruction associated with chronic obstructive pulmonary disease (COPD; including chronic bronchitis and emphysema)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F6091625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of asthma in children 5-11 years of age where combination therapy is indicated",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F142782\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Percentage of adverse events may be dose related; causation not established. Also see individual agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (7% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Nasopharyngitis (7% to 11%), upper respiratory tract infections (4% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (&lt;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Stomach discomfort (1% to 7%), oral candidiasis (1% to 6%), vomiting (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pharyngolaryngeal pain (6% to 9%), lower respiratory tract infection (3% to 8%), sinusitis (4% to 6%), bronchitis (5%), nasal congestion (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Influenza (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Agitation, anaphylaxis, angina, angioedema, anxiety, atrial arrhythmia, behavioral disturbances, bronchospasm, bruising, cataract, cough,  depression, dermatitis, dysphonia, exanthema, extrasystoles, glaucoma, growth velocity decreased (pediatric patients), hypercorticism symptoms, hyper-/hypotension, hyperglycemia, hypersensitivity reactions, hypokalemia, immunosuppression, intraocular pressure increased, muscle cramps, nausea, nervousness, palpitation, pruritus, rash, restlessness, sleep disturbances, tachycardia, throat irritation, tremor, urticaria, ventricular arrhythmia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F142762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to budesonide, formoterol, or any component of the formulation; need for acute bronchodilation in COPD or asthma  (including status asthmaticus)",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Hypersensitivity to inhaled lactose",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F142747\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal suppression: May cause hypercorticism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis. Withdrawal and discontinuation of a corticosteroid should be done slowly and carefully. Particular care is required when patients are transferred from systemic corticosteroids to inhaled products due to possible adrenal insufficiency or withdrawal from steroids, including an increase in allergic symptoms. Patients receiving &gt;20 mg per day of prednisone (or equivalent) may be most susceptible. Fatalities have occurred due to adrenal insufficiency in asthmatic patients during and after transfer from systemic corticosteroids to aerosol steroids; aerosol steroids do",
"     <b>",
"      not",
"     </b>",
"     provide the systemic steroid needed to treat patients having trauma, surgery, or infections. Do not use this product to transfer patients from oral corticosteroid therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma-related deaths:",
"     <b>",
"      [U.S. Boxed Warning]: Long-acting beta",
"      <sub>",
"       2",
"      </sub>",
"      -agonists (LABAs), such as formoterol, increase the risk of asthma-related deaths; budesonide and formoterol should only be used in patients not adequately controlled on other a long-term asthma control medication (ie, inhaled corticosteroid) or whose disease severity requires initiation of two maintenance therapies.",
"     </b>",
"     In a large, randomized, placebo-controlled U.S. clinical trial (SMART, 2006), salmeterol was associated with an increase in asthma-related deaths (when added to usual asthma therapy); risk is considered a class effect among all LABAs. Data are not available to determine if the addition of an inhaled corticosteroid lessens this increased risk of death associated with LABA use. Assess patients at regular intervals once asthma control is maintained on combination therapy to determine if step-down therapy is appropriate (without loss of asthma control), and the patient can be maintained on an inhaled corticosteroid only. LABAs are not appropriate in patients whose asthma is adequately controlled on low- or medium-dose inhaled corticosteroids",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone density: Long-term use may decrease bone mineral density in adults.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bronchospasm: Rarely, paradoxical bronchospasm may occur with use of inhaled bronchodilating agents; this should be distinguished from inadequate response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Immediate hypersensitivity reactions (urticaria, angioedema, rash, bronchospasm) have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immunosuppression: Prolonged use of corticosteroids may increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to vaccines. Exposure to chickenpox should be avoided; corticosteroids should not be used to treat ocular herpes simplex. Corticosteroids should not be used for cerebral malaria. Close observation is required in patients with latent tuberculosis and/or TB reactivity. Restrict use in active TB (only in conjunction with antituberculosis treatment).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lower respiratory infections: Pneumonia and other lower respiratory tract infections have been reported in patients with COPD following the use of inhaled corticosteroids; monitor COPD patients closely since pneumonia symptoms may overlap symptoms of exacerbations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Oral candidiasis: Infections with",
"     <i>",
"      Candida albicans",
"     </i>",
"     in the mouth and throat (thrush) have been reported with use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Serious effects/fatalities: Do not exceed recommended dose; serious adverse events, including fatalities, have been associated with excessive use of inhaled sympathomimetics.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vasculitis: Rare cases of vasculitis (Churg-Strauss syndrome) have been reported with use of inhaled corticosteroid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Appropriate use: Do",
"     <b>",
"      not",
"     </b>",
"     use for acute bronchospasm. Short-acting beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonist (eg, albuterol) should be used for acute symptoms and symptoms occurring between treatments. Do not initiate in patients with significantly worsening or acutely deteriorating asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (arrhythmia or hypertension or HF); beta agonists may cause elevation in blood pressure, heart rate and result in CNS stimulation/excitation. Beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonists may also increase risk of arrhythmias.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; COPD: Appropriate use: Do",
"     <b>",
"      not",
"     </b>",
"     use for acute episodes of COPD. Do",
"     <b>",
"      not",
"     </b>",
"     initiate in patients with significantly worsening or acutely deteriorating COPD. Data are not available to determine if LABA use increases the risk of death in patients with COPD.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonists may increase serum glucose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use caution; budesonide and formoterol are hepatically cleared.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypokalemia: Use with caution in patients with hypokalemia; beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonists may decrease serum potassium.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular disease: Use with caution in patients with cataracts and/or glaucoma; increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with prolonged use. Consider routine eye exams in chronic users.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Osteoporosis: Use with caution in patients with osteoporosis; high doses and/or long-term use of corticosteroids have been associated with increased bone loss and osteoporotic fractures.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorders: Use with caution in patients with seizure disorders; beta agonists may result in CNS stimulation/excitation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid disease: Changes in thyroid status may necessitate dosage adjustments; metabolic clearance of corticosteroids increases in hyperthyroid patients and decreases in hypothyroid ones.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for interactions: Use with caution in patients taking strong CYP3A4 inhibitors (see Drug Interactions); consider alternative agents that avoid or lessen the potential for CYP-mediated interactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics:",
"     <b>",
"      [U.S. Boxed Warning]: LABAs may increase the risk of asthma-related hospitalization in pediatric and adolescent patients.",
"     </b>",
"     Orally-inhaled and intranasal corticosteroids may cause a reduction in growth velocity in pediatric patients (~1 centimeter per year [range 0.3-1.8 cm per year] and related to dose and duration of exposure). To minimize the systemic effects of orally-inhaled and intranasal corticosteroids, each patient should be titrated to the lowest effective dose. Growth should be routinely monitored in pediatric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lactose: Some products (available in Canada) contain lactose; very rare anaphylactic reactions have been reported in patients with severe milk protein allergy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Discontinuation of therapy: Withdraw systemic therapy with gradual tapering of dose. There have been reports of systemic corticosteroid withdrawal symptoms (eg, joint/muscle pain, lassitude, depression) when withdrawing oral inhalation therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Patient information: Patients must be instructed to seek medical attention in cases where acute symptoms are not relieved by short-acting beta-agonist (not formoterol) or a previous level of response is diminished. Medical evaluation must not be delayed. Patients using inhaled, short acting beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonists should be instructed to discontinue routine use of these medications prior to beginning treatment with Symbicort&reg;; short acting agents should be reserved for symptomatic relief of acute symptoms. Patients should not use additional long-acting beta",
"     <sub>",
"      2",
"     </sub>",
"     -adrenergic agonists.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F142780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F142751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Blockers: May diminish the therapeutic effect of Beta2-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphotericin B: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Amphotericin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the bioavailability of Corticosteroids (Oral). Management: Consider separating doses by 2 or more hours. Budesonide enteric coated tablets could dissolve prematurely if given with drugs that lower gastric acid, with unknown impact on budesonide therapeutic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Corticosteroids (Orally Inhaled) may diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the tachycardic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atosiban: Beta2-Agonists may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers (Beta1 Selective): May diminish the bronchodilatory effect of Beta2-Agonists. Of particular concern with nonselective beta-blockers or higher doses of the beta1 selective beta-blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers (Nonselective): May diminish the bronchodilatory effect of Beta2-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: May diminish the therapeutic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Corticosteroids (Oral).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Caffeine: May enhance the adverse/toxic effect of Formoterol. Caffeine may enhance the hypokalemic effect of Formoterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Budesonide (Systemic, Oral Inhalation). Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Budesonide (Systemic, Oral Inhalation). Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Corticosteroids (Orally Inhaled). Management: Monitor for signs and symptoms of adrenal suppression if inhaled budesonide or mometasone are coadministered with a strong CYP3A4 inhibitor.  Avoid combining inhaled fluticasone with any strong CYP3A4 inhibitor.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of Budesonide (Systemic, Oral Inhalation).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Inhalational Anesthetics: May enhance the arrhythmogenic effect of Formoterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Beta2-Agonists may enhance the hypokalemic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the adverse/toxic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Budesonide (Systemic, Oral Inhalation). Management: Concurrent use of telaprevir with budesonide is not recommended, unless the risk for excessive systemic corticosteroid effects is outweighed by the potential benefits.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: May enhance the adverse/toxic effect of Formoterol. Theophylline Derivatives may enhance the hypokalemic effect of Formoterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Beta2-Agonists may enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the adverse/toxic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F142753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3071872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic and embryocidal effects were observed in animal studies when administered by inhalation at doses less than the maximum equivalent human dose. Also see individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F142774\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide: Enters breast milk/use caution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Formoterol: Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F5551127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Aerosol",
"     </b>",
"     (Symbicort Inhalation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80-4.5 mcg/ACT (6.9 g): $166.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     160-4.5 mcg/ACT (6 g): $192.06",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F142754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     FEV",
"     <sub>",
"      1",
"     </sub>",
"     , peak flow meter and/or other pulmonary function tests; monitor growth in pediatric patients, symptom relief, monitor for increased use if short-acting beta",
"     <sub>",
"      2",
"     </sub>",
"     -adrenergic agonists (may be a sign of asthma or COPD deterioration)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F142765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Foracort (MY);",
"     </li>",
"     <li>",
"      Symbicort Forte (TH);",
"     </li>",
"     <li>",
"      Symbicort Turbohaler (BE, DE, GB, IE);",
"     </li>",
"     <li>",
"      Symbicort Turbuhaler (AR, AT, AU, BB, BG, BM, BR, BS, BZ, CH, CL, CN, CO, CR, CZ, DK, DO, EE, FI, FR, GR, GT, GY, HK, HN, ID, IL, IT, JM, KP, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PR, PT, PY, RU, SE, SG, SR, SV, TH, TR, TT, TW, UY, VE);",
"     </li>",
"     <li>",
"      Symbiocort Turbuhaler (ES, MX);",
"     </li>",
"     <li>",
"      Vannair (HK, PE);",
"     </li>",
"     <li>",
"      Vent FB Inhaler (IN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F142746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Formoterol relaxes bronchial smooth muscle by selective action on beta",
"     <sub>",
"      2",
"     </sub>",
"     receptors with little effect on heart rate. Formoterol has a long-acting effect. Budesonide is a corticosteroid which controls the rate of protein synthesis, depresses the migration of polymorphonuclear leukocytes/fibroblasts, and reverses capillary permeability and lysosomal stabilization at the cellular level to prevent or control inflammation.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F142761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: Asthma: 15 minutes; maximum benefit: may take &ge;2 weeks",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Expert Panel Report 3, &ldquo;Guidelines for the Diagnosis and Management of Asthma,&rdquo;",
"      <i>",
"       Clinical Practice Guidelines",
"      </i>",
"      , National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007. Available at",
"      <a href=\"file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm\" target=\"_blank\">",
"       file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pohunek P, Kuna P, Jorup C, et al, &ldquo;Budesonide/Formoterol Improved Lung Function Compared With Budesonide Alone in Children With Asthma,&rdquo;",
"      <i>",
"       Pediatr Allergy Immunol",
"      </i>",
"      , 2006, 17(6):458-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/21/8536/abstract-text/16925692/pubmed\" id=\"16925692\" target=\"_blank\">",
"        16925692",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rennard SI, Tashkin DP, McElhattan J, et al, &ldquo;Long-Term Efficacy of Budesonide/Formoterol Administered Via One Pressurized Metered-Dose Inhaler in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease [poster],&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2008, 134:103001S.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rennard SI, Tashkin DP, McElhatta J, et al, &ldquo;Long-Term Tolerability of Budesonide and Formoterol Administered in One Pressurized Metered-Dose Inhaler in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2008, 134:103003S.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tashkin DP, Rennard SI, Martin P, et al, &ldquo;Efficacy of Budesonide/Formoterol Administered Via One Pressurized Metered-Dose Inhaler Over 6 Months in Patients With Chronic Obstructive Pulmonary Disease,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2008, 134:105001S.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8524 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-629A639819-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_21_8536=[""].join("\n");
var outline_f8_21_8536=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708638\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3071871\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142769\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142784\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142772\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142779\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3062966\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682318\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7310404\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142757\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5950028\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874387\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142759\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142758\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6091625\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142782\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142762\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142747\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142780\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142751\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142753\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3071872\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142774\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5551127\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142754\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142765\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142746\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142761\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8524\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8524|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/54/10086?source=related_link\">",
"      Budesonide and formoterol: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/39/43638?source=related_link\">",
"      Budesonide and formoterol: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_21_8537="Allergic contact dermatitis hand";
var content_f8_21_8537=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F82993%7EDERM%2F83192&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F82993%7EDERM%2F83192&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Allergic contact dermatitis of the hand",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Allergic contact dermatitis of the hand",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_21_8537=[""].join("\n");
var outline_f8_21_8537=null;
var title_f8_21_8538="Arrhythmias in COPD";
var content_f8_21_8538=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Arrhythmias in COPD",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/21/8538/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/21/8538/contributors\">",
"     Omar A Minai, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/21/8538/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/21/8538/contributors\">",
"     James K Stoller, MS, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/21/8538/contributors\">",
"     Leonard I Ganz, MD, FHRS, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/21/8538/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/21/8538/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/21/8538/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/21/8538/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of chronic obstructive pulmonary disease (COPD) includes gradually worsening shortness of breath and functional limitation, caused by a progressive decline in lung function and the development of co-morbid illnesses [",
"    <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/1\">",
"     1",
"    </a>",
"    ]. Multifocal atrial tachycardia, atrial fibrillation, and ventricular arrhythmias are common co-morbidities among patients with COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential contributing factors, occurrence rates, and management of arrhythmias in patients with COPD will be discussed here. The management of stable COPD and atrial and ventricular arrhythmia is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39338?source=see_link\">",
"     \"Management of stable chronic obstructive pulmonary disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39481?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/20/38216?source=see_link\">",
"     \"Multifocal atrial tachycardia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/6/39016?source=see_link\">",
"     \"Management of new onset atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/43/5817?source=see_link\">",
"     \"Rhythm control versus rate control in atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31034?source=see_link\">",
"     \"Approach to the diagnosis and treatment of wide QRS complex tachycardias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     POTENTIAL CONTRIBUTING FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple factors have been evaluated as possible contributors to the development of arrhythmias in patients with COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Some are related to comorbid disease processes with shared risk factors and others are more specifically related to COPD. Factors related to COPD that have been studied regarding their potential role in arrhythmia development are discussed in greater detail below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2391188\">",
"    <span class=\"h2\">",
"     Comorbid disease processes",
"    </span>",
"    &nbsp;&mdash;&nbsp;COPD shares risk factors (eg, age, smoking) with a number of disease processes and related treatments that are also associated with cardiac arrhythmias, including [",
"    <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Coronary heart disease",
"     </li>",
"     <li>",
"      Hypertensive heart disease",
"     </li>",
"     <li>",
"      Right",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      left ventricular failure",
"     </li>",
"     <li>",
"      Hypokalemia and hypomagnesemia",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       Digoxin",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These comorbid disease processes are discussed separately in the topics about the individual arrhythmias. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/22/361?source=see_link&amp;anchor=H440859983#H440859983\">",
"     \"Overview of atrial fibrillation\", section on 'Risk factors and disease associations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/20/38216?source=see_link&amp;anchor=H6#H6\">",
"     \"Multifocal atrial tachycardia\", section on 'Prevalence'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36228?source=see_link\">",
"     \"Atrial flutter: Epidemiology, classification, and risk factors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/17/14615?source=see_link\">",
"     \"Pathogenesis of ventricular arrhythmias in heart failure and cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/23/1401?source=see_link\">",
"     \"Left ventricular hypertrophy and arrhythmia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/26/28072?source=see_link&amp;anchor=H13658052#H13658052\">",
"     \"Basic approach to arrhythmias due to digoxin toxicity\", section on 'Digoxin-induced arrhythmias'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2391311\">",
"    <span class=\"h2\">",
"     Hypoxemia and respiratory acidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoxemia and respiratory acidosis have been identified in case series as factors associated with the development of arrhythmias among patients with COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The exact mechanisms by which hypoxemia and acidosis provoke arrhythmias are unclear. One possible explanation comes from the observation that norepinephrine levels (compared with normal values) were elevated in hypercapnic, hypoxemic patients with COPD who were hospitalized with fluid retention and peripheral edema [",
"    <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/5\">",
"     5",
"    </a>",
"    ]. It is hypothesized that the low arterial blood pressure caused by hypercapnia contributed to the elevation in norepinephrine. The catecholamine activation may in turn contribute to development of arrhythmias in such patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Theophylline",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     Theophylline",
"    </a>",
"    has numerous well-characterized cardiac effects, including a dose-dependent increase in heart rate, enhancement of atrial automaticity, and acceleration of intracardiac conduction. Theophylline is also associated with rhythm disturbances, such as sinus tachycardia, premature atrial beats, supraventricular tachycardia, atrial fibrillation, unifocal and multifocal atrial tachycardia, and ventricular arrhythmias. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/28/25031?source=see_link\">",
"     \"Role of methylxanthines in the treatment of COPD\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The frequency of atrial and ventricular arrhythmias increases with the serum",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    level, as illustrated in these studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a cross-sectional, retrospective study of 100 patients, the heart rate was directly related to the serum",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      concentration, and the serum theophylline concentration was the strongest independent predictor of arrhythmia [",
"      <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/6\">",
"       6",
"      </a>",
"      ]. Patients with a serum concentration of theophylline (10 to 20",
"      <span class=\"nowrap\">",
"       mcg/mL",
"      </span>",
"      [56 to 111",
"      <span class=\"nowrap\">",
"       micromol/L])",
"      </span>",
"      had an odds ratio for arrhythmia of 3.7, when compared with those patients who had serum theophylline levels of less than 2.5",
"      <span class=\"nowrap\">",
"       mcg/mL.",
"      </span>",
"      Multifocal atrial tachycardia (MAT) was found in 8 percent of patients with a serum theophylline concentration of 10 to 20",
"      <span class=\"nowrap\">",
"       mcg/mL",
"      </span>",
"      compared with 16 percent of those with values greater than 20",
"      <span class=\"nowrap\">",
"       mcg/mL.",
"      </span>",
"     </li>",
"     <li>",
"      One study prospectively evaluated arrhythmias among 16 patients with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      toxicity (a serum theophylline concentration exceeding 30",
"      <span class=\"nowrap\">",
"       mcg/mL)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/7\">",
"       7",
"      </a>",
"      ]. Sinus tachycardia and ventricular premature beats (VPBs) were the most common arrhythmias, occurring in 85 percent and 80 percent of subjects, respectively. The degree and severity of ventricular ectopy were largely influenced by the theophylline concentration and by coexistent conditions, such as underlying ischemic heart disease and age. Potentially life-threatening arrhythmias were rare (one patient had ventricular tachycardia), and only one patient required intervention with antiarrhythmic therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the magnitude of the effect of low therapeutic doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    on the occurrence of arrhythmias is unclear, and the current target serum level is lower (8 to 12",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    [44 to 67",
"    <span class=\"nowrap\">",
"     micromol/L])",
"    </span>",
"    than the range used in earlier studies (10 to 20",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    [56 to 111",
"    <span class=\"nowrap\">",
"     micromol/L])",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/6,8\">",
"     6,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Beta-adrenergic agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhaled beta-2 adrenergic agonists are a mainstay of therapy for COPD, but have the potential to increase heart rate and may increase cardiac arrhythmias via nonselective beta adrenergic effects [",
"    <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/9\">",
"     9",
"    </a>",
"    ]. However, a number of studies support the overall safety of inhaled selective beta-2 adrenergic agonists.",
"   </p>",
"   <p>",
"    The effect of nebulized",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    on sinus and atrioventricular (AV) node activity was examined in a study of 18 patients with asthma or mild COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/10\">",
"     10",
"    </a>",
"    ]. Nebulized albuterol (5 mg) shortened the sinus cycle length and sinus node recovery time. In addition, administration of albuterol enhanced the AV nodal conduction, reduced AV nodal refractory time, and decreased myocardial refractory time.",
"   </p>",
"   <p>",
"    Despite the effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    on sinus and AV nodal conduction noted above, clinical studies suggest that inhaled selective beta-adrenergic agonists infrequently cause serious arrhythmias. A meta-analysis of 33 randomized trials of patients receiving beta-agonists for obstructive airways disease revealed that beta-adrenergic agonists were associated with an increased risk of sinus tachycardia (RR 3.06, 95% CI 1.7-5.5), but were not associated with a significantly increased risk of major adverse cardiovascular events (composite endpoint of ventricular tachycardia, atrial fibrillation, syncope, heart failure, myocardial infarction, cardiac arrest, and sudden death) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/11\">",
"     11",
"    </a>",
"    ]. A single inhaled dose of beta-agonist increased the heart rate (mean 9 beats per minute, 95% CI 5.32-12.92). The effect of high-dose albuterol for COPD exacerbations was not addressed in this study.",
"   </p>",
"   <p>",
"    The effect of long-acting beta agonists (LABA) on heart rate and development of arrhythmia has also been examined. An analysis of the data from two trials examining the effect of LABAs on heart rate and cardiac arrhythmias found a slight increase in atrial tachycardias, but no increase in mean heart rate or risk of serious arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. A third trial of 1429 patients with COPD found that administration of a LABA (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/50/30500?source=see_link\">",
"     arformoterol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"     salmeterol",
"    </a>",
"    ) did not result in a statistically significant increase of atrial arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/12\">",
"     12",
"    </a>",
"    ]. The role of LABAs in the management of COPD is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39338?source=see_link&amp;anchor=H11#H11\">",
"     \"Management of stable chronic obstructive pulmonary disease\", section on 'Beta agonists'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12245074\">",
"    <span class=\"h2\">",
"     Cigarette smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether cigarette smoke exposure increases the risk of arrhythmias, independent of the degree of airflow obstruction, is unclear. It is hypothesized that active cigarette smoking may increase the risk of arrhythmias, due to profibrotic effects of nicotine on myocardial tissue or an increased susceptibility to catecholamines, but this has not been definitively demonstrated [",
"    <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/27/441?source=see_link&amp;anchor=H5#H5\">",
"     \"Supraventricular premature beats\", section on 'Etiology of APBs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Cardiac autonomic dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alterations of cardiac autonomic function may be important in the development of arrhythmia in patients with COPD. Some patients with COPD lack the normal pattern of cardiac circadian rhythm changes and some have a prolonged QT interval [",
"    <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. An absence of the normal nocturnal decrease in sympathetic tone among patients with COPD is suggested by 24-hour ambulatory electrocardiographic ECG recordings that do not reveal the typical nocturnal slowing of the heart rate. It has been suggested that this altered circadian pattern may predispose to arrhythmia [",
"    <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"     \"Acquired long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    QT dispersion (maximum QT interval minus minimum QT interval measured on an ECG) is an approximate measure of abnormal ventricular repolarization. An association has been noted between the presence of ventricular arrhythmias and increased QT dispersion in COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. The mechanism of increased QT dispersion in COPD and contribution of this effect to ventricular arrhythmias in COPD are not known. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/51/26425?source=see_link\">",
"     \"QT dispersion: Measurement and interpretation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/33/10778?source=see_link\">",
"     \"QT dispersion: Clinical applications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    P wave dispersion, the difference between the maximum (Pmax) and minimum (Pmin) duration of P waves on a surface ECG, is a measure of variability in intraatrial and interatrial conduction times. Initial studies suggest that increased P wave dispersion may be a predictor for development of atrial fibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Among patients with COPD, P wave dispersion is increased (greater variability in conduction times) compared with healthy controls, but it is not known whether this reflects co-morbid cardiac disease or a particular effect related to COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/21\">",
"     21",
"    </a>",
"    ]. The accuracy of P wave indices for predicting atrial arrhythmias needs further study [",
"    <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Ventricular diastolic dysfunction and respiratory failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of arrhythmias in COPD has been associated with concurrent left ventricular diastolic dysfunction. In a series of 22 patients with COPD, diastolic dysfunction was the only clinical variable predictive of ventricular premature beats [",
"    <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/22\">",
"     22",
"    </a>",
"    ]. Among patients with COPD, ventricular diastolic dysfunction may be related to right ventricular overload from pulmonary hypertension or to common causes such as increased age or comorbid myocardial ischemia or systemic hypertension. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43368?source=see_link\">",
"     \"Clinical manifestations and diagnosis of diastolic heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/28/15818?source=see_link\">",
"     \"Pathophysiology of diastolic heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Respiratory failure may also contribute to the risk of arrhythmias. In the preceding study of diastolic dysfunction in COPD, atrial premature beats correlated with hypoxemia and hypercarbia [",
"    <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/22\">",
"     22",
"    </a>",
"    ]. Furthermore, the number of arrhythmias significantly decreased when the respiratory failure improved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H874419\">",
"    <span class=\"h2\">",
"     Exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise does not appear to increase the risk of serious arrhythmias in patients with severe COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. In a case series of 122 patients with severe COPD, for example, ventricular arrhythmias (eg, ventricular premature beats [VPBs]",
"    <span class=\"nowrap\">",
"     &ge;6/min,",
"    </span>",
"    bigeminy, multiform VPBs, couplets, or nonsustained VT) developed during exercise in 12 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/24\">",
"     24",
"    </a>",
"    ]. None of these required specific treatment. Half of the patients who had ventricular arrhythmias during exercise had similar or lower grade ventricular arrhythmias at rest prior to testing. Patients without a history of ischemic heart disease or without any evidence of a cardiac arrhythmia at rest have a low likelihood of developing serious arrhythmias during exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11017?source=see_link\">",
"     \"Electrocardiographic changes during exercise ECG testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H883203\">",
"    <span class=\"h1\">",
"     OCCURRENCE OF ARRHYTHMIAS IN PATIENTS WITH COPD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence and prevalence of atrial and ventricular arrhythmias among patients with COPD varies widely among reported studies [",
"    <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/3,12,25,26\">",
"     3,12,25,26",
"    </a>",
"    ]. This variation may be due to differences in the study populations (eg, severity of COPD, presence of respiratory failure), the presence or absence of ventricular failure or underlying cardiac disease, the methodology used to record the arrhythmias (a single ECG versus a continuous 24-hour recording), and the medications used in management of COPD (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    , beta-adrenergic agonists). &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H883462\">",
"    <span class=\"h2\">",
"     Holter monitoring in stable COPD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of cardiac arrhythmias among patients with COPD was assessed in the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a cohort of 1429 patients with COPD who underwent 5226 Holter recordings, up to 40 percent of patients had atrial tachycardias in the absence of ongoing treatment with long-acting beta agonists [",
"      <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a cohort of 69 hypoxemic patients with severe but stable COPD who underwent continuous ECG recordings, episodes of supraventricular tachycardia occurred in 69 percent, while atrial fibrillation was the basic rhythm in 8 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/3\">",
"       3",
"      </a>",
"      ]. Premature ventricular beats (primarily multiform) and nonsustained ventricular tachycardia were present in 83 percent and 22 percent, respectively. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H883478\">",
"    <span class=\"h2\">",
"     Specific arrhythmias associated with COPD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multifocal atrial tachycardia (MAT), atrial fibrillation, and ventricular arrhythmias often complicate the course of COPD, particularly during acute exacerbations [",
"    <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H883521\">",
"    <span class=\"h3\">",
"     Multifocal atrial tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multifocal atrial tachycardia (MAT) is defined by the following electrocardiographic findings (",
"    <a class=\"graphic graphic_waveform graphicRef70173 \" href=\"UTD.htm?13/22/13671\">",
"     waveform 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Discrete P waves with at least",
"      <strong>",
"       three",
"      </strong>",
"      different morphologies",
"     </li>",
"     <li>",
"      Atrial rate faster than 100 beats per minute",
"     </li>",
"     <li>",
"      Separation of the P waves by isoelectric intervals",
"     </li>",
"     <li>",
"      Variable P-P intervals, P-R duration, and R-R intervals",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The evaluation and diagnosis of MAT are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/20/38216?source=see_link&amp;anchor=H23844503#H23844503\">",
"     \"Multifocal atrial tachycardia\", section on 'Clinical manifestations and diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with COPD, MAT most commonly develops in the setting of an acute exacerbation, but is also associated with certain drugs (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    ), other pulmonary processes (eg, pneumonia, pulmonary embolism, hypoxemia), and nonpulmonary disorders such as hypokalemia, hypomagnesemia, and chronic renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/20/38216?source=see_link&amp;anchor=H23843900#H23843900\">",
"     \"Multifocal atrial tachycardia\", section on 'Associated clinical conditions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with chronic airway obstruction who were admitted to the hospital with acute respiratory failure, MAT was noted in 17 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/29\">",
"     29",
"    </a>",
"    ]. However, this report may be an overestimate of the frequency of MAT as concomitant medications were not reported, and the study was performed in an era when",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    and nonselective beta agonists were widely used. In a systematic review that examined the contribution of COPD to the development of MAT, COPD was present in 55 percent of patients with MAT, making it the most common pulmonary disorder associated with MAT [",
"    <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rapid ventricular response in MAT likely contributes to the respiratory impairment in patients with COPD, either by elevation of the left ventricular diastolic pressure by limiting the portion of the cardiac cycle spent in diastole [",
"    <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/30\">",
"     30",
"    </a>",
"    ]. This increase in left ventricular pressure then can contribute to pulmonary hypertension, potentially exacerbating right atrial hypertension and distension and augmenting the stimulus for MAT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H883569\">",
"    <span class=\"h3\">",
"     Atrial fibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial fibrillation is characterized by an irregularly irregular rhythm and the absence of distinct P waves on the ECG and can be a cause of worsening dyspnea and hypoxemia among patients with COPD. The diagnosis of atrial fibrillation and the evaluation of predisposing conditions are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/22/361?source=see_link\">",
"     \"Overview of atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28522?source=see_link\">",
"     \"Epidemiology of and risk factors for atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28602?source=see_link\">",
"     \"Atrial fibrillation and flutter after cardiac surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among subjects in the Copenhagen City Heart Study who met spirometric criteria for COPD, the incidence of new onset atrial fibrillation was 0.9 percent over five years of followup compared with 0.4 percent among those with normal spirometry [",
"    <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/25\">",
"     25",
"    </a>",
"    ]. In several series of ambulatory patients with COPD, the risk of developing atrial fibrillation increased as the forced expiratory volume in one second (FEV1) decreased [",
"    <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/25,31,32\">",
"     25,31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The frequency of atrial fibrillation is also increased during acute exacerbations of COPD. In a series of 590 patients hospitalized with an exacerbation of COPD, atrial fibrillation was noted in 8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/26\">",
"     26",
"    </a>",
"    ]. Cardiomegaly was noted in 20 percent, suggesting that comorbid cardiac disease may have been contributory.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H883562\">",
"    <span class=\"h3\">",
"     Ventricular arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventricular arrhythmias, ranging from isolated ventricular premature beats (VPBs) to nonsustained ventricular tachycardia, are often noted on 24 hour ECG monitoring of patients with COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/3,17\">",
"     3,17",
"    </a>",
"    ]. The evaluation and diagnosis of ventricular tachycardia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31034?source=see_link\">",
"     \"Approach to the diagnosis and treatment of wide QRS complex tachycardias\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/41/13974?source=see_link\">",
"     \"Nonsustained VT in the absence of apparent structural heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The frequency of ventricular arrhythmias among patients with COPD has been examined in several studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 69 patients with COPD severe enough to require nocturnal supplemental oxygen, PVCs were noted in 83 percent and nonsustained ventricular tachycardia in 22 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a case control study, PVCs were more common among outpatients with COPD than controls (924",
"      <span class=\"nowrap\">",
"       +/-",
"      </span>",
"      493 beats versus 35",
"      <span class=\"nowrap\">",
"       +/-",
"      </span>",
"      23 beats, p = 0.009); nonsustained ventricular tachycardia was noted in 8 patients (27 percent) with COPD, but none of the controls [",
"      <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a series of 590 patients hospitalized with an exacerbation of COPD, ventricular arrhythmias occurred in 19 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1291532\">",
"    <span class=\"h2\">",
"     General measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;When treating arrhythmias in patients with COPD, treatment measures are tailored to the specific type and severity of the arrhythmia and the unique clinical characteristics of each patient. Certain general measures are useful in the majority of patients, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Optimize COPD management &ndash; Optimal management of COPD includes providing supplemental oxygen (aiming for a pulse oxygen saturation of 90 to 94 percent), reversing bronchoconstriction, and treating hypercapnia with bronchodilation and respiratory support. Selective, short-acting beta adrenergic agents are a key therapy for exacerbations of COPD and should be titrated to provide adequate bronchodilation and relief of dyspnea without excess cardiac chronotropic effects. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39338?source=see_link\">",
"       \"Management of stable chronic obstructive pulmonary disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23641?source=see_link&amp;anchor=H7#H7\">",
"       \"Management of acute exacerbations of chronic obstructive pulmonary disease\", section on 'Oxygen therapy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23641?source=see_link&amp;anchor=H9#H9\">",
"       \"Management of acute exacerbations of chronic obstructive pulmonary disease\", section on 'Beta adrenergic agonists'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Correct precipitating conditions &ndash; Acute myocardial ischemia, and electrolyte, acid-base, and metabolic abnormalities, particularly hypokalemia and hypomagnesemia, should be identified and treated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/20/38216?source=see_link&amp;anchor=H754567#H754567\">",
"       \"Multifocal atrial tachycardia\", section on 'Magnesium and potassium repletion'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/6/39016?source=see_link&amp;anchor=H5#H5\">",
"       \"Management of new onset atrial fibrillation\", section on 'Evaluation for an underlying cause'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31034?source=see_link&amp;anchor=H31#H31\">",
"       \"Approach to the diagnosis and treatment of wide QRS complex tachycardias\", section on 'Management'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Avoid the concurrent use of drugs that can prolong the QT interval &ndash; Drugs that can prolong the QT interval include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"       clarithromycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"       ketoconazole",
"      </a>",
"      , and certain psychotropic medications (",
"      <a class=\"graphic graphic_table graphicRef57431 \" href=\"UTD.htm?2/48/2830\">",
"       table 1",
"      </a>",
"      ). QT prolongation can initiate ventricular tachycardias, particularly torsade de pointes [",
"      <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/33\">",
"       33",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"       \"Acquired long QT syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cautious dosing or discontinuation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      &ndash; For patients on chronic theophylline therapy, maintain the serum level at 8 to 12",
"      <span class=\"nowrap\">",
"       mcg/mL",
"      </span>",
"      (44 to 67",
"      <span class=\"nowrap\">",
"       micromol/L),",
"      </span>",
"      since 85 percent of its beneficial effect occurs at a level of 12",
"      <span class=\"nowrap\">",
"       mcg/mL",
"      </span>",
"      or less, and theophylline may be arrhythmogenic even at levels previously considered within the therapeutic range (10 to 20",
"      <span class=\"nowrap\">",
"       mcg/mL",
"      </span>",
"      or 56 to 111",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/34\">",
"       34",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Theophylline'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/28/25031?source=see_link\">",
"       \"Role of methylxanthines in the treatment of COPD\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12244686\">",
"    <span class=\"h2\">",
"     Multifocal atrial tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific antiarrhythmic therapy is indicated for MAT when the rapid ventricular response produces or worsens ischemia, heart failure, or peripheral perfusion. The general management of multifocal atrial tachycardia is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/20/38216?source=see_link&amp;anchor=H754560#H754560\">",
"     \"Multifocal atrial tachycardia\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When pharmacologic intervention is indicated for MAT, the preferred agents are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef83358 \" href=\"UTD.htm?10/28/10700\">",
"     table 2",
"    </a>",
"    ). Due to the potential risk of bronchoconstriction from beta blocking agents, verapamil is most commonly used as the initial agent in patients with COPD. Metoprolol is reserved for use when verapamil does not provide adequate rate control. The dosing and administration of verapamil and metoprolol are presented in the table (",
"    <a class=\"graphic graphic_table graphicRef83358 \" href=\"UTD.htm?10/28/10700\">",
"     table 2",
"    </a>",
"    ) and are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/20/38216?source=see_link&amp;anchor=H754574#H754574\">",
"     \"Multifocal atrial tachycardia\", section on 'Pharmacologic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When administering",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    to patients with COPD, we continuously monitor pulse oximetry and provide supplemental oxygen, aiming for a pulse oxygen saturation of 90 to 94 percent. Theoretically, calcium channel blockers may lower the partial pressure of arterial oxygen in patients with lung disease due to the relief of hypoxic vasoconstriction in pulmonary",
"    <span class=\"nowrap\">",
"     arteries/arterioles",
"    </span>",
"    supplying poorly ventilated areas. This possibility was supported by pooled data from several studies that found a mean reduction in arterial oxygen tension from 105 to 78 mmHg after the administration of a calcium channel blocker, a change that may be clinically significant [",
"    <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23641?source=see_link&amp;anchor=H7#H7\">",
"     \"Management of acute exacerbations of chronic obstructive pulmonary disease\", section on 'Oxygen therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite concerns about beta-blockers triggering bronchoconstriction in patients with COPD, a systematic review found that the beta-1 selective agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    resulted in a decrease in ventricular response of 24 to 40 percent among the four studies described (45 patients) without exacerbating respiratory symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/28\">",
"     28",
"    </a>",
"    ]. A separate systematic review did not find evidence of adverse respiratory effects with short-term use of cardioselective beta-blockers in patients with COPD who did not have active wheezing or bronchoconstriction [",
"    <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/36\">",
"     36",
"    </a>",
"    ]. For patients with COPD that is not characterized by a bronchospastic component, cautious use of metoprolol is a reasonable option, when",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    is ineffective. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3704?source=see_link&amp;anchor=H7#H7\">",
"     \"Major side effects of beta blockers\", section on 'Increased airways resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     Verapamil",
"    </a>",
"    is generally used in preference to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    for MAT due to the limited supportive data for diltiazem, although success was reported with an initial bolus and maintenance infusion in a case series [",
"    <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/28\">",
"     28",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1291289\">",
"    <span class=\"h2\">",
"     Atrial fibrillation and supraventricular tachyarrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/European",
"    </span>",
"    Society of Cardiology has published recommendations for the management of atrial fibrillation in patients with pulmonary disease (",
"    <a class=\"graphic graphic_table graphicRef83353 \" href=\"UTD.htm?24/43/25277\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Urgent electrical cardioversion of supraventricular tachyarrhythmias is indicated if hemodynamic collapse, angina, or heart failure is present (",
"      <a class=\"graphic graphic_table graphicRef72962 \" href=\"UTD.htm?12/49/13084\">",
"       table 4",
"      </a>",
"      ). For patients who have not been anticoagulated or have suboptimal anticoagulation, a transesophageal echocardiogram (TEE) is frequently performed to exclude intracardiac thrombus just prior to cardioversion. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6473?source=see_link\">",
"       \"Overview of the acute management of tachyarrhythmias\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/6/39016?source=see_link&amp;anchor=H448750704#H448750704\">",
"       \"Management of new onset atrial fibrillation\", section on 'Indications for urgent cardioversion'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/6/39016?source=see_link&amp;anchor=H532809012#H532809012\">",
"       \"Management of new onset atrial fibrillation\", section on 'Anticoagulation'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Pharmacologic therapy to terminate the arrhythmia or control the ventricular response is indicated if these maneuvers are unsuccessful (",
"      <a class=\"graphic graphic_table graphicRef83353 \" href=\"UTD.htm?24/43/25277\">",
"       table 3",
"      </a>",
"      ) . The management of atrial fibrillation and other supraventricular tachyarrhythmias is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/6/39016?source=see_link\">",
"       \"Management of new onset atrial fibrillation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6473?source=see_link\">",
"       \"Overview of the acute management of tachyarrhythmias\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"       flecainide",
"      </a>",
"      (not available as an intravenous preparation in the United States) is an alternative therapy for restoring normal sinus rhythm in patients with COPD and atrial fibrillation [",
"      <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/38\">",
"       38",
"      </a>",
"      ]. One study randomized 30 of patients with supraventricular tachycardia, acute respiratory failure, and COPD randomized patients to one of two regimens: flecainide 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      intravenously over ten minutes followed by a continuous infusion of 1.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      over one hour or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      0.15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      infused over five minutes followed by a continuous infusion of 0.005",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per minute for one hour [",
"      <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/39\">",
"       39",
"      </a>",
"      ]. Flecainide reversed the arrhythmia in 80 percent of cases compared to only 33 percent with verapamil. Furthermore, 91 percent of patients who responded to flecainide did so after the initial bolus injection of 2",
"      <span class=\"nowrap\">",
"       mg/kg.",
"      </span>",
"      Although these results are encouraging, more data are needed. Flecainide should be avoided in patients with underlying left heart failure or myocardial ischemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22426?source=see_link&amp;anchor=H8701769#H8701769\">",
"       \"Restoration of sinus rhythm in atrial fibrillation\", section on 'Flecainide'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Antithrombotic therapy is initiated in patients with atrial fibrillation based on standard practices, although anticoagulation has not been studied specifically in patients with AF in the setting of chronic lung disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link\">",
"       \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35257?source=see_link\">",
"       \"Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The majority of patients presenting with atrial fibrillation will require slowing of the ventricular rate to improve symptoms. Intravenous administration of a nondihydropyridine calcium channel antagonist (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      ) is the preferred pharmacologic therapy for new onset atrial fibrillation in patients with COPD (",
"      <a class=\"graphic graphic_table graphicRef83353 \" href=\"UTD.htm?24/43/25277\">",
"       table 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/27,40,41\">",
"       27,40,41",
"      </a>",
"      ]. These agents have a weak bronchodilator effect, rather than the potential bronchoconstrictive effect of beta blockers. Doses of verapamil and diltiazem are provided in the table (",
"      <a class=\"graphic graphic_table graphicRef83353 \" href=\"UTD.htm?24/43/25277\">",
"       table 3",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       Digoxin",
"      </a>",
"      offers no advantages over calcium channel blockers for patients with atrial fibrillation and COPD, except in the presence of heart failure (",
"      <a class=\"graphic graphic_table graphicRef83353 \" href=\"UTD.htm?24/43/25277\">",
"       table 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Several effective antiarrhythmic drugs must be used with caution or not at all in patients with COPD [",
"      <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/37\">",
"       37",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Beta blockers are contraindicated in patients with uncontrolled bronchospasm and wheezing. Similar considerations apply to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"       propafenone",
"      </a>",
"      , a Class IC antiarrhythmic (",
"      <a class=\"graphic graphic_table graphicRef56600 \" href=\"UTD.htm?2/52/2892\">",
"       table 5",
"      </a>",
"      ), and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       sotalol",
"      </a>",
"      , a class III agent, which have beta-blocking properties.",
"     </li>",
"     <li>",
"      Because of the overlap of many risk factors between COPD and coronary heart disease and the frequent co-existence of these two processes, Class IA and IC antiarrhythmic drugs (",
"      <a class=\"graphic graphic_table graphicRef56600 \" href=\"UTD.htm?2/52/2892\">",
"       table 5",
"      </a>",
"      ) should be used with caution as these drugs are contraindicated in patients with coronary heart disease.",
"     </li>",
"     <li>",
"      Adenosine, which has a rapid onset of action and an effect that is blocked by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      , may provoke bronchospasm and must be used with caution in patients with COPD [",
"      <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Chronic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      therapy causes pulmonary toxicity in 5 to 15 percent of cases. It should therefore be used in only carefully selected patients with COPD (eg, those with an accessory pathway) due to concerns about superimposed lung toxicity in those with limited respiratory reserve [",
"      <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/42\">",
"       42",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=see_link\">",
"       \"Major side effects of amiodarone\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The American College of",
"      <span class=\"nowrap\">",
"       Cardiology/American",
"      </span>",
"      Heart",
"      <span class=\"nowrap\">",
"       Association/European",
"      </span>",
"      Society of Cardiology guidelines suggest avoiding beta-adrenergic agonists in patients with atrial fibrillation based on low quality evidence [",
"      <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/38\">",
"       38",
"      </a>",
"      ]. We make the decision regarding use of beta adrenergic agonists on a case by case basis. For patients with difficulty achieving rate control but without active bronchoconstriction, it is reasonable to avoid or minimize the dose of beta agonists. On the other hand, for patients with dyspnea and uncontrolled bronchoconstriction, treatment with beta2 selective adrenergic agonists is appropriate and generally well-tolerated.",
"     </li>",
"     <li>",
"      We generally avoid initiation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      in patients with atrial fibrillation, particularly if rate control has been problematic [",
"      <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/38\">",
"       38",
"      </a>",
"      ]. For patients with new onset atrial fibrillation in the setting of chronic theophylline therapy, we ensure that the dose of theophylline is in the low therapeutic range (8 to 12",
"      <span class=\"nowrap\">",
"       mcg/mL",
"      </span>",
"      [44 to 67",
"      <span class=\"nowrap\">",
"       micromol/L])",
"      </span>",
"      or discontinue it if it is not felt to be vital to the treatment of the patient&rsquo;s COPD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Symptomatic ventricular arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic ventricular arrhythmias require prompt treatment. Electrical cardioversion should immediately be performed if hemodynamic collapse, myocardial ischemia, or ventricular failure is present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11050?source=see_link\">",
"     \"Cardioversion for specific arrhythmias\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/47/21241?source=see_link\">",
"     \"Ventricular arrhythmias in heart failure and cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pharmacologic treatment is indicated if the patient is not hemodynamically compromised, but is symptomatic. The pharmacologic therapy of ventricular arrhythmias is discussed separately, but some caveats regarding treatment in patients with COPD are discussed below. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/47/21241?source=see_link\">",
"     \"Ventricular arrhythmias in heart failure and cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16217?source=see_link\">",
"     \"Role of antiarrhythmic drugs for ventricular arrhythmias in patients with a prior myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31034?source=see_link&amp;anchor=H31#H31\">",
"     \"Approach to the diagnosis and treatment of wide QRS complex tachycardias\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When managing patients with COPD and ventricular arrhythmias, it is important to consider potential adverse effects of antiarrhythmic medications on lung function.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       Amiodarone",
"      </a>",
"      is the most commonly used agent for ventricular arrhythmias. While patients with COPD are not necessarily at higher risk of amiodarone pulmonary toxicity, they may be at higher risk for respiratory failure if toxicity occurs [",
"      <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/27\">",
"       27",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/4/29767?source=see_link\">",
"       \"Amiodarone pulmonary toxicity\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       Sotalol",
"      </a>",
"      has a significant nonselective beta-blocking effect, which can trigger bronchospasm, and thus is usually avoided in patients with COPD and active bronchoconstriction. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/10/28841?source=see_link&amp;anchor=H21#H21\">",
"       \"Therapeutic use and major side effects of sotalol\", section on 'Major side effects'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/9/10389?source=see_link\">",
"       Mexiletine",
"      </a>",
"      is another alternative, but is of variable efficacy and interacts with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      via CYP1A2 inhibition.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An implantable cardioverter-defibrillator (ICD) may be indicated for long-term management of patients with clinically significant (symptomatic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sustained) ventricular arrhythmias. In a case-control study of patients with COPD and a left ventricular ejection fraction of 35 percent or less, patients with an ICD had a lower total mortality (odds ratio 0.18, 95% CI 0.06&ndash;0.56) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/43\">",
"     43",
"    </a>",
"    ]. A discussion of the indications for ICD placement is provided separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/62/15338?source=see_link\">",
"     \"Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43385?source=see_link\">",
"     \"Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28202146\">",
"    <span class=\"h2\">",
"     Asymptomatic ventricular arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal management of asymptomatic ventricular arrhythmias in patients with COPD is not known. Approximately 4 percent of patients with COPD experience sudden or unexplained death; however, the role of serious ventricular arrhythmias in these deaths is poorly defined [",
"    <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The benefit of treating asymptomatic ventricular arrhythmias in an attempt to lessen the risk of sudden death in these patients also remains unproven. Antiarrhythmic drugs may actually increase risk of arrhythmias, worsen heart failure, and cause lung injury [",
"    <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/27,45\">",
"     27,45",
"    </a>",
"    ]. Thus, considerable caution should be exercised in administering antiarrhythmic drugs to asymptomatic patients with COPD and ventricular arrhythmias. Given the potential risks, we avoid pharmacologic antiarrhythmic therapy in these patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/36/36424?source=see_link&amp;anchor=H8259402#H8259402\">",
"     \"Clinical significance and treatment of ventricular premature beats\", section on 'Summary and recommendations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/26/22952?source=see_link&amp;anchor=H21#H21\">",
"     \"Management of nonsustained ventricular tachycardia\", section on 'Management of symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H231974\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of arrhythmias on the prognosis of patients with COPD is dependent on the clinical setting (eg, severity of COPD exacerbation), presence of comorbidities (eg, shock, heart failure, stroke, renal insufficiency), and the specific arrhythmia [",
"    <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/46\">",
"     46",
"    </a>",
"    ]. Among 69 ambulatory patients monitored as part of the nocturnal oxygen therapy trial, the presence of asymptomatic ventricular arrhythmias was not a predictor of death [",
"    <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/3\">",
"     3",
"    </a>",
"    ]. In contrast, among patients hospitalized with an exacerbation of COPD, the development of MAT was associated with increased mortality with one series reporting an in-hospital mortality of 46 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/27\">",
"     27",
"    </a>",
"    ]. MAT and other serious atrial arrhythmias can be associated with malignant ventricular arrhythmias in patients with acute respiratory failure [",
"    <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of 590 patients hospitalized with an acute exacerbation of COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/26\">",
"     26",
"    </a>",
"    ], atrial fibrillation and ventricular arrhythmia were independent predictors of death at one year (OR 1.91, 95% CI 1.10-3.31) and (OR 2.27, 95% CI 1.14-4.51), respectively. Furthermore, among patients admitted to the hospital with respiratory failure due to COPD, ventricular arrhythmias were associated with a mortality rate of 70 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/21/8538/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H777653\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1920009\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Both supraventricular and ventricular arrhythmias are common among patients with COPD. The risk is further elevated during periods of acute exacerbation and thoracic surgery; however, even patients with stable COPD have a fairly high rate of rhythm disturbances. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H883203\">",
"       'Occurrence of arrhythmias in patients with COPD'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Multiple factors contribute to the development of arrhythmias in patients with COPD, including hypoxemia, respiratory acidosis, electrolyte disturbances, medications, systemic hypertension, cardiac autonomic dysfunction, coronary heart disease, and heart failure. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Potential contributing factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Characteristic features of multifocal atrial tachycardia (MAT) include discrete P waves with at least",
"      <strong>",
"       three",
"      </strong>",
"      different morphologies, an atrial rate faster than 100",
"      <span class=\"nowrap\">",
"       beats/min,",
"      </span>",
"      isoelectric intervals separating the P waves, and variability in the P-P intervals, P-R duration, and R-R intervals. MAT most commonly develops in the setting of an acute exacerbation of COPD, but is also associated with certain drugs (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      ), other pulmonary processes (eg, pneumonia, pulmonary embolism, hypoxemia), and metabolic disorders. (See",
"      <a class=\"local\" href=\"#H883521\">",
"       'Multifocal atrial tachycardia'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/20/38216?source=see_link\">",
"       \"Multifocal atrial tachycardia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Atrial fibrillation is characterized by an irregularly irregular rhythm and the absence of distinct P waves. New onset of atrial fibrillation is associated with advancing COPD and is in the differential diagnosis of worsening dyspnea and hypoxemia among patients with COPD. (See",
"      <a class=\"local\" href=\"#H883569\">",
"       'Atrial fibrillation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/22/361?source=see_link\">",
"       \"Overview of atrial fibrillation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ventricular tachyarrhythmias, ranging from isolated premature ventricular contractions (PVCs) to nonsustained ventricular tachycardia, are common in ambulatory and hospitalized patients with COPD. It appears unlikely that asymptomatic ventricular arrhythmias adversely impact mortality among ambulatory patients with COPD. (See",
"      <a class=\"local\" href=\"#H883562\">",
"       'Ventricular arrhythmias'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H231974\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1920017\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The treatment of arrhythmias in patients with COPD begins with correction of hypoxemia, respiratory acidosis, electrolyte abnormalities (eg, hypokalemia, hypomagnesemia), and cardiac ischemia. Medications that can prolong the QT interval are removed and arrhythmogenic drugs such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      are decreased in dose or discontinued. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Short-acting selective beta-2 adrenergic agents are key components of therapy for exacerbations of COPD. For patients with tachyarrhythmias, the dose should be titrated to provide adequate bronchodilation and relief of dyspnea without excess cardiac chronotropic effects. (See",
"      <a class=\"local\" href=\"#H1291532\">",
"       'General measures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with MAT in the setting of an exacerbation of COPD, the main treatment is directed toward reversing bronchoconstriction and improving gas exchange. Pharmacologic therapy for MAT is indicated when a rapid ventricular response produces or worsens ischemia, heart failure, peripheral perfusion, or oxygenation. For most patients with symptomatic MAT in the setting of COPD, we suggest using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      rather than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"       metoprolol",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ); metoprolol is reserved for patients without active bronchoconstriction in whom adequate rate control is not achieved with verapamil. The dosing and administration of these agents is provided in the table (",
"      <a class=\"graphic graphic_table graphicRef83358 \" href=\"UTD.htm?10/28/10700\">",
"       table 2",
"      </a>",
"      ) and discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/20/38216?source=see_link&amp;anchor=H754574#H754574\">",
"       \"Multifocal atrial tachycardia\", section on 'Pharmacologic therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Urgent electrical cardioversion of supraventricular tachyarrhythmias (eg, atrial fibrillation, atrial flutter) is indicated if hemodynamic collapse, angina, or heart failure is present. Pharmacologic therapy is used to control the ventricular response if cardioversion is unsuccessful or not performed (",
"      <a class=\"graphic graphic_table graphicRef83353 \" href=\"UTD.htm?24/43/25277\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1291289\">",
"       'Atrial fibrillation and supraventricular tachyarrhythmias'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with atrial fibrillation and COPD, we suggest using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      rather than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"       metoprolol",
"      </a>",
"      in patients who require ventricular rate control (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Metoprolol is reserved for patients who do not respond to the calcium channel blockers and do not have uncontrolled bronchoconstriction. For those with an accessory pathway or heart failure,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      may be preferred as outlined in the table (",
"      <a class=\"graphic graphic_table graphicRef83353 \" href=\"UTD.htm?24/43/25277\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1291289\">",
"       'Atrial fibrillation and supraventricular tachyarrhythmias'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/22/361?source=see_link&amp;anchor=H10#H10\">",
"       \"Overview of atrial fibrillation\", section on 'Treatment issues'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/6/39016?source=see_link\">",
"       \"Management of new onset atrial fibrillation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with atrial fibrillation, antithrombotic therapy is initiated based on standard practices, although anticoagulation has not been studied specifically for patients with AF in the setting of chronic lung disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link\">",
"       \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35257?source=see_link\">",
"       \"Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Several drugs that are effective antiarrhythmics (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       sotalol",
"      </a>",
"      , adenosine,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/9/10389?source=see_link\">",
"       mexiletine",
"      </a>",
"      ) must be used with caution or not at all in patients with COPD. (See",
"      <a class=\"local\" href=\"#H1291289\">",
"       'Atrial fibrillation and supraventricular tachyarrhythmias'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Symptomatic ventricular arrhythmias'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Urgent treatment is required for symptomatic ventricular arrhythmias. Electrical cardioversion is performed immediately if hemodynamic collapse, myocardial ischemia, or ventricular failure is present. The use of antiarrhythmic agents for ventricular arrhythmias is discussed separately. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Symptomatic ventricular arrhythmias'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/47/21241?source=see_link\">",
"       \"Ventricular arrhythmias in heart failure and cardiomyopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with COPD and asymptomatic ventricular arrhythmias, we avoid antiarrhythmic therapy due to uncertain benefit and the potential for a proarrhythmic effect. Gas exchange abnormalities and metabolic disturbances are corrected. (See",
"      <a class=\"local\" href=\"#H1291532\">",
"       'General measures'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H28202146\">",
"       'Asymptomatic ventricular arrhythmias'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1257562\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Alejandro Arroliga, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/21/8538/abstract/1\">",
"      Minai OA, Benditt J, Martinez FJ. Natural history of emphysema. Proc Am Thorac Soc 2008; 5:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/21/8538/abstract/2\">",
"      Sode BF, Dahl M, Nordestgaard BG. Myocardial infarction and other co-morbidities in patients with chronic obstructive pulmonary disease: a Danish nationwide study of 7.4 million individuals. Eur Heart J 2011; 32:2365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/21/8538/abstract/3\">",
"      Shih HT, Webb CR, Conway WA, et al. Frequency and significance of cardiac arrhythmias in chronic obstructive lung disease. Chest 1988; 94:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/21/8538/abstract/4\">",
"      G&oacute;recka D. Cardiac arrhythmias in chronic obstructive pulmonary disease. Monaldi Arch Chest Dis 1997; 52:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/21/8538/abstract/5\">",
"      Anand IS, Chandrashekhar Y, Ferrari R, et al. Pathogenesis of congestive state in chronic obstructive pulmonary disease. Studies of body water and sodium, renal function, hemodynamics, and plasma hormones during edema and after recovery. Circulation 1992; 86:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/21/8538/abstract/6\">",
"      Bittar G, Friedman HS. The arrhythmogenicity of theophylline. A multivariate analysis of clinical determinants. Chest 1991; 99:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/21/8538/abstract/7\">",
"      Sessler CN, Cohen MD. Cardiac arrhythmias during theophylline toxicity. A prospective continuous electrocardiographic study. Chest 1990; 98:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/21/8538/abstract/8\">",
"      Huerta C, Lanes SF, Garc&iacute;a Rodr&iacute;guez LA. Respiratory medications and the risk of cardiac arrhythmias. Epidemiology 2005; 16:360.",
"     </a>",
"    </li>",
"    <li>",
"     Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2011. www.goldcopd.org (Accessed on February 10, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/21/8538/abstract/10\">",
"      Kallergis EM, Manios EG, Kanoupakis EM, et al. Acute electrophysiologic effects of inhaled salbutamol in humans. Chest 2005; 127:2057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/21/8538/abstract/11\">",
"      Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest 2004; 125:2309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/21/8538/abstract/12\">",
"      Hanrahan JP, Grogan DR, Baumgartner RA, et al. Arrhythmias in patients with chronic obstructive pulmonary disease (COPD): occurrence frequency and the effect of treatment with the inhaled long-acting beta2-agonists arformoterol and salmeterol. Medicine (Baltimore) 2008; 87:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/21/8538/abstract/13\">",
"      Donohue JF, Hanania NA, Fogarty C, et al. Long-term safety of nebulized formoterol: results of a twelve-month open-label clinical trial. Ther Adv Respir Dis 2008; 2:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/21/8538/abstract/14\">",
"      D'Alessandro A, Boeckelmann I, Hammwh&ouml;ner M, Goette A. Nicotine, cigarette smoking and cardiac arrhythmia: an overview. Eur J Cardiovasc Prev Rehabil 2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/21/8538/abstract/15\">",
"      T&uuml;kek T, Yildiz P, Atilgan D, et al. Effect of diurnal variability of heart rate on development of arrhythmia in patients with chronic obstructive pulmonary disease. Int J Cardiol 2003; 88:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/21/8538/abstract/16\">",
"      Stewart AG, Waterhouse JC, Howard P. The QTc interval, autonomic neuropathy and mortality in hypoxaemic COPD. Respir Med 1995; 89:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/21/8538/abstract/17\">",
"      Yildiz P, T&uuml;kek T, Akkaya V, et al. Ventricular arrhythmias in patients with COPD are associated with QT dispersion. Chest 2002; 122:2055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/21/8538/abstract/18\">",
"      Zulli R, Donati P, Nicosia F, et al. Increased QT dispersion: a negative prognostic finding in chronic obstructive pulmonary disease. Intern Emerg Med 2006; 1:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/21/8538/abstract/19\">",
"      Dilaveris PE, Gialafos JE. P-wave dispersion: a novel predictor of paroxysmal atrial fibrillation. Ann Noninvasive Electrocardiol 2001; 6:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/21/8538/abstract/20\">",
"      Magnani JW, Williamson MA, Ellinor PT, et al. P wave indices: current status and future directions in epidemiology, clinical, and research applications. Circ Arrhythm Electrophysiol 2009; 2:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/21/8538/abstract/21\">",
"      T&uuml;kek T, Yildiz P, Akkaya V, et al. Factors associated with the development of atrial fibrillation in COPD patients: the role of P-wave dispersion. Ann Noninvasive Electrocardiol 2002; 7:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/21/8538/abstract/22\">",
"      Incalzi RA, Pistelli R, Fuso L, et al. Cardiac arrhythmias and left ventricular function in respiratory failure from chronic obstructive pulmonary disease. Chest 1990; 97:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/21/8538/abstract/23\">",
"      Celli BR. Pulmonary rehabilitation in patients with COPD. Am J Respir Crit Care Med 1995; 152:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/21/8538/abstract/24\">",
"      Cheong TH, Magder S, Shapiro S, et al. Cardiac arrhythmias during exercise in severe chronic obstructive pulmonary disease. Chest 1990; 97:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/21/8538/abstract/25\">",
"      Buch P, Friberg J, Scharling H, et al. Reduced lung function and risk of atrial fibrillation in the Copenhagen City Heart Study. Eur Respir J 2003; 21:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/21/8538/abstract/26\">",
"      Fuso L, Incalzi RA, Pistelli R, et al. Predicting mortality of patients hospitalized for acutely exacerbated chronic obstructive pulmonary disease. Am J Med 1995; 98:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/21/8538/abstract/27\">",
"      Payne, RM. Management of arrhythmias in patients with severe lung disease. Clin Pulm Med 1994; 1:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/21/8538/abstract/28\">",
"      McCord J, Borzak S. Multifocal atrial tachycardia. Chest 1998; 113:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/21/8538/abstract/29\">",
"      Hudson LD, Kurt TL, Petty TL, Genton E. Arrhythmias associated with acute respiratory failure in patients with chronic airway obstruction. Chest 1973; 63:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/21/8538/abstract/30\">",
"      Engel TR, Radhagopalan S. Treatment of multifocal atrial tachycardia by treatment of pulmonary insufficiency: or is it vice versa? Chest 2000; 117:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/21/8538/abstract/31\">",
"      Holtzman D, Aronow WS, Mellana WM, et al. Electrocardiographic abnormalities in patients with severe versus mild or moderate chronic obstructive pulmonary disease followed in an academic outpatient pulmonary clinic. Ann Noninvasive Electrocardiol 2011; 16:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/21/8538/abstract/32\">",
"      Shibata Y, Watanabe T, Osaka D, et al. Impairment of pulmonary function is an independent risk factor for atrial fibrillation: the Takahata study. Int J Med Sci 2011; 8:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/21/8538/abstract/33\">",
"      Greenberg, YJ, Rosenfeld, LE. Evaluating and managing arrhythmias in COPD. J Respir Dis 1995; 16:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/21/8538/abstract/34\">",
"      Rogers RM, Owens GR, Pennock BE. The pendulum swings again. Toward a rational use of theophylline. Chest 1985; 87:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/21/8538/abstract/35\">",
"      Kastor JA. Multifocal atrial tachycardia. N Engl J Med 1990; 322:1713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/21/8538/abstract/36\">",
"      Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005; :CD003566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/21/8538/abstract/37\">",
"      Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol. 2006; 48:e149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/21/8538/abstract/38\">",
"      European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31:2369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/21/8538/abstract/39\">",
"      Barranco F, Sanchez M, Rodriguez J, Guerrero M. Efficacy of flecainide in patients with supraventricular arrhythmias and respiratory insufficiency. Intensive Care Med 1994; 20:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/21/8538/abstract/40\">",
"      Ganz LI, Friedman PL. Supraventricular tachycardia. N Engl J Med 1995; 332:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/21/8538/abstract/41\">",
"      Fuster V, Ryd&eacute;n LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114:e257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/21/8538/abstract/42\">",
"      Kennedy JI Jr. Clinical aspects of amiodarone pulmonary toxicity. Clin Chest Med 1990; 11:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/21/8538/abstract/43\">",
"      Razak E, Kamireddy S, Saba S. Implantable cardioverter-defibrillators confer survival benefit in patients with chronic obstructive pulmonary disease. Pacing Clin Electrophysiol 2010; 33:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/21/8538/abstract/44\">",
"      McGarvey LP, Magder S, Burkhart D, et al. Cause-specific mortality adjudication in the UPLIFT&reg; COPD trial: findings and recommendations. Respir Med 2012; 106:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/21/8538/abstract/45\">",
"      Pratt CM. Asymptomatic ventricular arrhythmias in patients with obstructive lung disease. Should they be treated? Chest 1988; 94:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/21/8538/abstract/46\">",
"      Steer J, Gibson GJ, Bourke SC. Predicting outcomes following hospitalization for acute exacerbations of COPD. QJM 2010; 103:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/21/8538/abstract/47\">",
"      Kleiger RE, Senior RM. Longterm electrocardiographic monitoring of ambulatory patients with chronic airway obstruction. Chest 1974; 65:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/21/8538/abstract/48\">",
"      Roberts CM, Stone RA, Lowe D, et al. Co-morbidities and 90-day outcomes in hospitalized COPD exacerbations. COPD 2011; 8:354.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1454 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-BD1901CB76-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_21_8538=[""].join("\n");
var outline_f8_21_8538=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H777653\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      POTENTIAL CONTRIBUTING FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2391188\">",
"      Comorbid disease processes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2391311\">",
"      Hypoxemia and respiratory acidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Theophylline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Beta-adrenergic agonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12245074\">",
"      Cigarette smoking",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Cardiac autonomic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Ventricular diastolic dysfunction and respiratory failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H874419\">",
"      Exercise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H883203\">",
"      OCCURRENCE OF ARRHYTHMIAS IN PATIENTS WITH COPD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H883462\">",
"      Holter monitoring in stable COPD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H883478\">",
"      Specific arrhythmias associated with COPD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H883521\">",
"      - Multifocal atrial tachycardia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H883569\">",
"      - Atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H883562\">",
"      - Ventricular arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1291532\">",
"      General measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12244686\">",
"      Multifocal atrial tachycardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1291289\">",
"      Atrial fibrillation and supraventricular tachyarrhythmias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Symptomatic ventricular arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28202146\">",
"      Asymptomatic ventricular arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H231974\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H777653\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1920009\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1920017\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1257562\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1454\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1454|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/48/2830\" title=\"table 1\">",
"      Causes of long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/28/10700\" title=\"table 2\">",
"      Heart rate control of MAT in COPD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/43/25277\" title=\"table 3\">",
"      Heart rate control of atrial fib in COPD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/49/13084\" title=\"table 4\">",
"      Electrical cardioversion AF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/52/2892\" title=\"table 5\">",
"      Vaughan Williams classification of antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1454|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?13/22/13671\" title=\"waveform 1\">",
"      Multifocal atrial tachycardia ECG",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/4/29767?source=related_link\">",
"      Amiodarone pulmonary toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35257?source=related_link\">",
"      Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=related_link\">",
"      Antithrombotic therapy to prevent embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31034?source=related_link\">",
"      Approach to the diagnosis and treatment of wide QRS complex tachycardias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28602?source=related_link\">",
"      Atrial fibrillation and flutter after cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36228?source=related_link\">",
"      Atrial flutter: Epidemiology, classification, and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/26/28072?source=related_link\">",
"      Basic approach to arrhythmias due to digoxin toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11050?source=related_link\">",
"      Cardioversion for specific arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43368?source=related_link\">",
"      Clinical manifestations and diagnosis of diastolic heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39481?source=related_link\">",
"      Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/36/36424?source=related_link\">",
"      Clinical significance and treatment of ventricular premature beats",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11017?source=related_link\">",
"      Electrocardiographic changes during exercise ECG testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28522?source=related_link\">",
"      Epidemiology of and risk factors for atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/23/1401?source=related_link\">",
"      Left ventricular hypertrophy and arrhythmia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=related_link\">",
"      Major side effects of amiodarone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3704?source=related_link\">",
"      Major side effects of beta blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23641?source=related_link\">",
"      Management of acute exacerbations of chronic obstructive pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/6/39016?source=related_link\">",
"      Management of new onset atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/26/22952?source=related_link\">",
"      Management of nonsustained ventricular tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39338?source=related_link\">",
"      Management of stable chronic obstructive pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/20/38216?source=related_link\">",
"      Multifocal atrial tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/41/13974?source=related_link\">",
"      Nonsustained VT in the absence of apparent structural heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/22/361?source=related_link\">",
"      Overview of atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6473?source=related_link\">",
"      Overview of the acute management of tachyarrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/17/14615?source=related_link\">",
"      Pathogenesis of ventricular arrhythmias in heart failure and cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/28/15818?source=related_link\">",
"      Pathophysiology of diastolic heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/33/10778?source=related_link\">",
"      QT dispersion: Clinical applications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/51/26425?source=related_link\">",
"      QT dispersion: Measurement and interpretation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22426?source=related_link\">",
"      Restoration of sinus rhythm in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/43/5817?source=related_link\">",
"      Rhythm control versus rate control in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16217?source=related_link\">",
"      Role of antiarrhythmic drugs for ventricular arrhythmias in patients with a prior myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/62/15338?source=related_link\">",
"      Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43385?source=related_link\">",
"      Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/28/25031?source=related_link\">",
"      Role of methylxanthines in the treatment of COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/27/441?source=related_link\">",
"      Supraventricular premature beats",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/10/28841?source=related_link\">",
"      Therapeutic use and major side effects of sotalol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/47/21241?source=related_link\">",
"      Ventricular arrhythmias in heart failure and cardiomyopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_21_8539="Succinylcholine hyperK";
var content_f8_21_8539=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F74108&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F74108&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diseases causing ACh receptor upregulation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        The diseases listed below are associated with a risk of severe hyperkalemia following succinylcholine administration:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Denervating injuries (eg, stroke, spinal cord injury), after 72 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Denervating diseases (eg, multiple sclerosis, amyotrophic lateral sclerosis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inherited myopathies (eg, Duchenne's muscular dystrophy)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Burns, after 72 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Crush injuries, after 72 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rhabdomyolysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prolonged total body immobilization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe, prolonged intraabdominal infections",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_21_8539=[""].join("\n");
var outline_f8_21_8539=null;
var title_f8_21_8540="Child Pugh classification";
var content_f8_21_8540=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F78401&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F78401&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Child-Pugh classification of severity of cirrhosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Parameter",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Points assigned",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        1",
"       </td>",
"       <td class=\"subtitle2\">",
"        2",
"       </td>",
"       <td class=\"subtitle2\">",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ascites",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"       <td>",
"        Slight",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bilirubin",
"       </td>",
"       <td>",
"        &lt;2 mg/dL (&lt;34.2 micromol/liter)",
"       </td>",
"       <td>",
"        2 to 3 mg/dL (34.2 to 51.3 micromol/liter)",
"       </td>",
"       <td>",
"        &gt;3 mg/dL (&gt;51.3 micromol/liter)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Albumin",
"       </td>",
"       <td>",
"        &gt;3.5 g/dL (35 g/liter)",
"       </td>",
"       <td>",
"        2.8 to 3.5 g/dL (28 to 35 g/liter)",
"       </td>",
"       <td>",
"        &lt;2.8 g/dL (&lt;28 g/liter)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"4\">",
"        Prothrombin time",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Seconds over control",
"       </td>",
"       <td class=\"sublist_other\">",
"        &lt;4",
"       </td>",
"       <td class=\"sublist_other\">",
"        4 to 6",
"       </td>",
"       <td class=\"sublist_other\">",
"        &gt;6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        INR",
"       </td>",
"       <td class=\"sublist_other\">",
"        &lt;1.7",
"       </td>",
"       <td class=\"sublist_other\">",
"        1.7 to 2.3",
"       </td>",
"       <td class=\"sublist_other\">",
"        &gt;2.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Encephalopathy",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Grade 1 to 2",
"       </td>",
"       <td>",
"        Grade 3 to 4",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Modified Child-Pugh classification of the severity of liver disease according to the degree of ascites, the serum concentrations of bilirubin and albumin, the prothrombin time, and the degree of encephalopathy. A total Child-Turcotte-Pugh score of 5 to 6 is considered class A (well-compensated disease); 7 to 9 is class B (significant functional compromise); and 10 to 15 is class C (decompensated disease). These classes correlate with one- and two-year patient survival: class A: 100 and 85 percent; class B: 80 and 60 percent; and class C: 45 and 35 percent.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_21_8540=[""].join("\n");
var outline_f8_21_8540=null;
var title_f8_21_8541="MSAFP level by gestational age";
var content_f8_21_8541=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F76646&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F76646&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    AFP by gestational age",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 313px; height: 301px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    AFP: alpha-fetoprotein.",
"    <br>",
"     Median maternal serum levels in unaffected pregnancies calculated from in-house data at Women and Infants Hospital, Providence, Rhode Island. These data are representative and not intended or appropriate for use in other laboratories",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_21_8541=[""].join("\n");
var outline_f8_21_8541=null;
var title_f8_21_8542="Tcu-380A IUD";
var content_f8_21_8542=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F56136&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F56136&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Tcu-380A (Paragard&reg;) intrauterine contraceptive device",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 287px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This device consists of a T-shaped polyethylene frame with 380 mm2 of exposed surface consisting of fine copper wire wound around the vertical stem and each of the horizontal arms. There is a 3-mm ball at the base of the stem to decrease the risk of cervical perforation [1]. A white or clear polyethylene monofilament string is knotted through this ball.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_21_8542=[""].join("\n");
var outline_f8_21_8542=null;
var title_f8_21_8543="Cancer presentations with a median survival of 6 months or less";
var content_f8_21_8543=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PALC%2F87452&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PALC%2F87452&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical characteristics of patients with a variety of tumor types and a median survival of 6 months or less",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Solid cancer by site",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Breast neoplasms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"2\">",
"        Breast cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Any metastatic breast carcinoma with one or more of the following presentations:",
"       </td>",
"       <td>",
"        <p>",
"         KPS &lt;60 (ECOG performance status &gt;2)",
"        </p>",
"        <p>",
"         Moderate to severe hypercalcemia (serum calcium &gt;11.2 mg/dL)",
"        </p>",
"        <p>",
"         Epidural spinal cord compression with decreased ability to walk",
"        </p>",
"        <p>",
"         Serum C-reactive protein &gt;10 mg/L and serum albumin &lt;3.5 g/dL",
"        </p>",
"        Peritoneal or leptomeningeal metastases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Any metastatic breast carcinoma with three or more of the following presentations:",
"       </td>",
"       <td>",
"        <p>",
"         KPS &lt;80 (ECOG performance status &ge;2)",
"        </p>",
"        <p>",
"         Serum lactate dehydrogenase &gt;500 IU/L",
"        </p>",
"        <p>",
"         Any liver metastasis",
"        </p>",
"        <p>",
"         At least 2 sites of metastases",
"        </p>",
"        <p>",
"         Disease-free interval from initial presentation to metastatic disease of &lt;24 months",
"        </p>",
"        <p>",
"         Recurrent or refractory disease after initial chemotherapy (unresponsive to treatment)",
"        </p>",
"        Tumor with estrogen receptor-negative plus progesterone receptor-negative status",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Metastatic breast carcinoma with brain metastases and one or more of the following presentations:",
"       </td>",
"       <td>",
"        <p>",
"         KPS &lt;80 (ECOG performance status &ge;2)",
"        </p>",
"        <p>",
"         &ge;2 brain metastases plus extracranial metastases",
"        </p>",
"        Tumor with estrogen receptor-negative and progesterone receptor-negative status",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Central nervous system neoplasms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"2\">",
"        Primary brain cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Glioblastoma with one or more of the following presentations:",
"       </td>",
"       <td>",
"        <p>",
"         KPS &lt;70 (ECOG performance status &ge;2)",
"        </p>",
"        <p>",
"         Suboptimal surgical resection or unresectable disease",
"        </p>",
"        Progressive or refractory disease despite initial treatment (unresponsive to treatment)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Glioblastoma with two or more of the following presentations:",
"       </td>",
"       <td>",
"        <p>",
"         KPS &lt;90 (ECOG performance status &ge;1)",
"        </p>",
"        <p>",
"         Age &gt;55 years",
"        </p>",
"        <p>",
"         Recurrent disease after initial treatment",
"        </p>",
"        <p>",
"         Lesion in critical hemispheric brain region",
"        </p>",
"        <p>",
"         Tumor volume &gt;50 cm",
"         <sup>",
"          3",
"         </sup>",
"         prior to resection",
"        </p>",
"        <p>",
"         Hemoglobin &lt;12 g/dL",
"        </p>",
"        Platelet count &gt;upper limit normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Digestive system neoplasms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"2\">",
"        Colorectal cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Metastatic colorectal cancer with one or more of the following presentations:",
"       </td>",
"       <td>",
"        <p>",
"         KPS &lt;70 (ECOG performance status &ge;2)",
"        </p>",
"        <p>",
"         Age &gt;75 years",
"        </p>",
"        Brain metastases with KPS &lt;80, age &gt;70 years, extracranial metastases, or &ge;2 brain lesions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Metastatic colorectal carcinoma with two or more of the following presentations:",
"       </td>",
"       <td>",
"        <p>",
"         KPS &lt;90 (ECOG performance status &ge;1)",
"        </p>",
"        <p>",
"         Peritoneal carcinomatosis",
"        </p>",
"        <p>",
"         &gt;2 metastatic sites",
"        </p>",
"        <p>",
"         Malignant ascites",
"        </p>",
"        Refractory disease after chemotherapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"2\">",
"        Esophageal and gastric cancers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Locally advanced or metastatic esophageal or gastric cancer with one or more of the following presentations:",
"       </td>",
"       <td>",
"        <p>",
"         KPS &lt;80 (ECOG performance status &gt;1)",
"        </p>",
"        Recurrent or refractory disease, with disease-free interval &lt;6 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Locally advanced or metastatic esophageal or gastric cancer with two or more of the following presentations:",
"       </td>",
"       <td>",
"        <p>",
"         KPS &lt;90 (ECOG performance status &ge;1)",
"        </p>",
"        <p>",
"         Liver metastases",
"        </p>",
"        <p>",
"         Peritoneal metastases",
"        </p>",
"        <p>",
"         Serum alkaline phosphatase &gt;100 U/L",
"        </p>",
"        <p>",
"         Serum lactate dehydrogenase &gt;200 IU/L",
"        </p>",
"        Serum hemoglobin &lt;11 g/dL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"2\">",
"        Hepatobiliary and pancreatic cancers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Locally advanced or metastatic biliary tract cancer (cholangiocarcinoma or gallbladder carcinoma) or pancreatic cancer with one or more of the following presentations:",
"       </td>",
"       <td>",
"        <p>",
"         KPS &lt;90 (ECOG performance status &ge; 1)",
"        </p>",
"        <p>",
"         Biliary obstruction with jaundice, or total bilirubin level &gt;10 mg/dL",
"        </p>",
"        <p>",
"         Recurrent or refractory disease after initial chemotherapy",
"        </p>",
"        <p>",
"         Liver, peritoneal, or distant metastases",
"        </p>",
"        <p>",
"         Portal vein thrombosis or other vascular invasion",
"        </p>",
"        <p>",
"         Gross residual disease (visible cancer) after resection",
"        </p>",
"        <p>",
"         Poorly differentiated or infiltrating disease",
"        </p>",
"        <p>",
"         Serum albumin &lt;3.5 g/dL or &gt;10 percent weight loss",
"        </p>",
"        <p>",
"         Serum lactate dehydrogenase &gt;500 IU/L",
"        </p>",
"        <p>",
"         Episode of extremity venous thromboembolism or pulmonary embolis",
"        </p>",
"        Malignant ascites",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Any hepatocellular carcinoma with one or more of the following presentations:",
"       </td>",
"       <td>",
"        <p>",
"         KPS &lt;60 (ECOG performance status &gt;2)",
"        </p>",
"        <p>",
"         Severe end-stage cirrhosis",
"        </p>",
"        <p>",
"         Large tumor size (maximum tumor diameter &gt;10 cm or tumor volume &gt;70 percent liver volume)",
"        </p>",
"        Any brain metastasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Unresectable locally advanced or metastatic hepatocellular carcinoma with two or more of the following presentations:",
"       </td>",
"       <td>",
"        <p>",
"         KPS &lt;90 (ECOG performance status &ge;1)",
"        </p>",
"        <p>",
"         Extrahepatic metastases",
"        </p>",
"        <p>",
"         Moderate to severe symptomatic cirrhosis (such as jaundice, ascites, fatigue or bleeding)",
"        </p>",
"        <p>",
"         Alpha-fetoprotein level &ge;400 ng/mL",
"        </p>",
"        Portal vein thrombosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Head and neck neoplasms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"2\">",
"        Head and neck squamous cell carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Recurrent, refractory, or metastatic head and neck squamous cell carcinoma with one or more of the following presentations:",
"       </td>",
"       <td>",
"        <p>",
"         KPS &lt;90 (ECOG performance status &ge;1",
"        </p>",
"        <p>",
"         Recurrence of disease with any metastases &gt;10 percent weight loss",
"        </p>",
"        <p>",
"         Muscle invasion or residual tumor at primary site",
"        </p>",
"        <p>",
"         Pretreatment anemia (hemoglobin &lt;11 g/dL)",
"        </p>",
"        Moderate to severe hypercalcemia (serum calcium &gt;11.2 mg/dL)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"2\">",
"        Melanoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Advanced or metastatic melanoma with one or more of the following presentations:",
"       </td>",
"       <td>",
"        <p>",
"         KPS &lt;80 (ECOG performance status &ge;2)",
"        </p>",
"        <p>",
"         Serum lactate dehydrogenase &gt;2 x the upper limit of normal",
"        </p>",
"        <p>",
"         Moderate to severe hypercalcemia (serum calcium &gt;11.2 mg/dL)",
"        </p>",
"        <p>",
"         Metastasis to the brain or spine",
"        </p>",
"        Metastases to liver and one other site",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Thoracic neoplasms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"2\">",
"        Non&ndash;small cell lung cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Any locally advanced or metastatic non-small cell lung cancer with one or more of the following presentations:",
"       </td>",
"       <td>",
"        <p>",
"         KPS &lt;70 (ECOG performance status &gt;2)",
"        </p>",
"        <p>",
"         Weight loss of &gt;5 percent or serum albumin &lt;3 g/dL",
"        </p>",
"        <p>",
"         Liver metastases",
"        </p>",
"        <p>",
"         Bone or bone marrow metastases",
"        </p>",
"        <p>",
"         Brain metastases with neurological symptoms, KPS &lt;70, age &gt;65 years, or extracranial metastases",
"        </p>",
"        <p>",
"         Pericardial effusion",
"        </p>",
"        <p>",
"         Pleural effusion with evidence of distant metastases",
"        </p>",
"        <p>",
"         Serum hemoglobin &lt;12 g/dL",
"        </p>",
"        <p>",
"         Serum calcium &gt;11 mg/dL",
"        </p>",
"        Age &gt;70 years with pleural effusion, hypoalbuminemia, elevated serum lactate dehydrogenase, or hyponatremia (levels outside the normal range)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Urogenital neoplasms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"2\">",
"        Female genital neoplasms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Locally advanced or metastatic ovarian, uterine endometrial or uterine cervical cancer with regional or distant spread, and one or more of the following presentations:",
"       </td>",
"       <td>",
"        <p>",
"         KPS &lt;60 (ECOG performance status &gt;2)",
"        </p>",
"        <p>",
"         Serum calcium &gt;11.2 mg/dL",
"        </p>",
"        <p>",
"         Brain metastases plus extracranial lesion or KPS &lt;70 or &ge;2 brain metastases",
"        </p>",
"        <p>",
"         Intestinal obstruction without successful repair, or urinary tract obstruction with stent placement",
"        </p>",
"        Unresectable disease due to location of disease or comorbid illness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Locally advanced or metastatic ovarian, uterine endometrial or uterine cervical cancer with regional or distant spread, and two or more of the following presentations:",
"       </td>",
"       <td>",
"        <p>",
"         KPS &lt;80 (ECOG performance status &gt;1)",
"        </p>",
"        <p>",
"         Recurrent or refractory disease (unresponsive to treatment)",
"        </p>",
"        <p>",
"         Disease-free interval from diagnosis to disease recurrence or persistence of &lt;6 months",
"        </p>",
"        <p>",
"         Suboptimal resection with bulky residual disease",
"        </p>",
"        <p>",
"         Significant weight loss (&gt;5 percent)",
"        </p>",
"        Extra-abdominal metastases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"2\">",
"        Prostate cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hormone-refractory metastatic prostate cancer with one or more of the following presentations:",
"       </td>",
"       <td>",
"        <p>",
"         KPS &lt;60 (ECOG performance status &gt;2)",
"        </p>",
"        <p>",
"         KPS &lt;80 (ECOG performance status &gt;1) or significant fatigue, plus hemoglobin &lt;12 g/dL",
"        </p>",
"        <p>",
"         Hemoglobin &lt;10 g/dL",
"        </p>",
"        Spinal cord compression with decreased ability to walk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Urologic neoplasms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"2\">",
"        Bladder and renal cell carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Locally advanced or metastatic bladder or renal cell carcinoma with one or more of the following presentations:",
"       </td>",
"       <td>",
"        <p>",
"         KPS &lt;70 (ECOG performance status &gt;2)",
"        </p>",
"        <p>",
"         Brain metastases with &ge;2 metastases, or extracranial metastases",
"        </p>",
"        Serum calcium &gt;11.2 mg/dL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Locally advanced or metastatic bladder or renal cell carcinoma with three or more of the following presentations:",
"       </td>",
"       <td>",
"        <p>",
"         KPS &lt;80 (ECOG performance status &ge;2)",
"        </p>",
"        <p>",
"         Hemoglobin &lt;11.5 g/dL",
"        </p>",
"        <p>",
"         Serum lactate dehydrogenase &gt;300 IU/L or alkaline phosphatase &gt;220 U/L",
"        </p>",
"        <p>",
"         Disease-free interval from initial presentation to metastatic disease or disease progression &le;1 year",
"        </p>",
"        Visceral metastases",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Presentations associated with a median survival of six months or less.",
"    <div class=\"footnotes\">",
"     KPS: Karnofsky Performance Status; ECOG: Eastern Cooperative Oncology Group.",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Salpeter SR, Malter DS, Luo EJ, et al. Systematic review of cancer presentations with a median survival of six months or less. J Palliat Med 2012; 15:175. Copyright &copy; 2012 Mary Ann Liebert, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_21_8543=[""].join("\n");
var outline_f8_21_8543=null;
